Science Corp. Raises $230M for Wireless Retinal Implant Pending FDA Decision
Science Corporation, a startup developing a wireless retinal implant to restore vision, announced Thursday it has secured $230 million in Series C funding as it awaits a decision from the Food and Drug Administration (FDA) on its lead product, PRIMA. The funding brings the company’s total capital raised since its founding in 2021 to approximately $490 million, signaling strong investor confidence in the potential of this novel technology.
Restoring Sight with Light and Implants
PRIMA is designed for individuals with late-stage macular degeneration, a leading cause of vision loss. The system combines specially designed glasses that project near-infrared light with a small retinal implant. Recent clinical trial results, published in the New England Journal of Medicine, demonstrated that the system restored central vision and improved visual acuity in participants after 12 months. Central vision is crucial for tasks like reading and recognizing faces. The trial’s findings are a key component of the company’s submission to the FDA.
The Series C funding round included participation from Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital, a diverse group of investors suggesting broad interest in the company’s approach. Macular degeneration affects millions worldwide, and current treatment options are limited, often focused on slowing the progression of the disease rather than restoring lost vision.
How PRIMA Works: A Closer Look at the Technology
Macular degeneration damages the macula, a small area in the center of the retina responsible for sharp, central vision. PRIMA aims to bypass the damaged cells by directly stimulating the remaining healthy cells in the retina. The glasses worn by patients project patterns of near-infrared light onto the retina. This light is then converted into electrical signals by the implanted device, which stimulates the retinal cells, creating a visual percept. The New England Journal of Medicine study details the methodology and results of the clinical trials, including the specific parameters of the light stimulation and the methods used to assess visual acuity.
It’s important to note that PRIMA doesn’t aim to restore perfect vision. Instead, it seeks to provide a functional improvement in vision, allowing patients to perform daily tasks more easily. The clinical trials assessed improvements in visual acuity and the ability to navigate obstacles, providing a measure of the system’s functional benefit. The study authors acknowledge limitations, including the relatively small sample size and the require for longer-term follow-up to assess the durability of the visual improvements.
European Launch Anticipated, FDA Decision Pending
Science Corporation anticipates launching PRIMA in Europe later this year, leveraging the regulatory pathways available there. The company is now focused on awaiting the FDA’s decision regarding approval for use in the United States. The FDA review process typically involves a thorough evaluation of the clinical trial data, manufacturing processes, and the overall risk-benefit profile of the device.
The FDA’s decision will be a significant milestone for Science Corporation and for the field of retinal prosthetics. If approved, PRIMA would represent a new treatment option for individuals with late-stage macular degeneration who have limited or no other effective therapies. The company’s founder, Max Hodak, has previously been involved in other neurotechnology ventures, bringing a wealth of experience to this endeavor. O. Rose Broderick, reporting for STAT News, covers the health policies and technologies impacting people with disabilities, and her work highlights the potential of PRIMA to address a significant unmet need.
The Landscape of Retinal Implants and Vision Restoration
PRIMA is not the only retinal implant under development. Several other companies and research groups are exploring different approaches to restoring vision, including devices that stimulate different parts of the retina and those that use different types of stimulation. The Bionic Eye Research Australia, for example, is conducting research on various retinal implant technologies. These efforts reflect a growing understanding of the visual system and the potential to overcome the limitations of current treatments.
However, retinal implants face several challenges, including the complexity of the retina, the need for long-term biocompatibility of the implanted device, and the difficulty of providing a natural and high-resolution visual experience. The clinical trials for PRIMA have shown promising results, but further research is needed to optimize the technology and address these challenges.
What’s Next for Science Corporation and Retinal Implants?
Following the FDA decision, Science Corporation will focus on scaling up manufacturing and preparing for commercial launch. The company will also likely continue to conduct clinical trials to gather more data on the long-term safety and efficacy of PRIMA, and to explore its potential use in other retinal conditions.
Beyond PRIMA, the field of vision restoration is rapidly evolving. Researchers are investigating gene therapies, stem cell therapies, and other innovative approaches to treat macular degeneration and other causes of vision loss. The convergence of these technologies holds the promise of restoring sight to millions of people worldwide. You can find more information about ongoing research in vision restoration from organizations like the Foundation Fighting Blindness (https://www.fightingblindness.org/).
For individuals with macular degeneration, staying informed about the latest research and treatment options is crucial. Consulting with a qualified ophthalmologist is the best way to determine the most appropriate course of action. The American Academy of Ophthalmology (https://www.aao.org/) provides resources and information for patients and healthcare professionals.